No Added Value of Duloxetine in Patients With Chronic Pain due to Hip or Knee Osteoarthritis: A Cluster-Randomized Trial.
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
30
09
2021
received:
21
04
2021
accepted:
02
12
2021
pubmed:
7
1
2022
medline:
29
4
2022
entrez:
6
1
2022
Statut:
ppublish
Résumé
To assess the effectiveness of duloxetine in addition to usual care in patients with chronic osteoarthritis (OA) pain. The cost-effectiveness and whether the presence of symptoms of centralized pain alters the response to duloxetine were secondary objectives. We conducted an open-label, cluster-randomized trial. Patients with chronic hip or knee OA pain who had an insufficient response to acetaminophen and nonsteroidal antiinflammatory drugs were included. Randomization took place at the general practice level, and patients received duloxetine (60 mg/day) in addition to usual care or usual care alone. The presence of centralized pain was defined as a modified PainDETECT Questionnaire score >12. The primary outcome measure was Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores (scale 0-20) at 3 months after the initiation of treatment. Our aim was to detect a difference between the groups of a clinically relevant effect of 1.9 points (effect size 0.4). We used a linear mixed model with repeated measurements to analyze the data. In total, 133 patients were included, and 132 patients were randomized into treatment groups. A total of 66 patients (at 31 practices) were randomized to receive duloxetine in addition to usual care, and 66 patients (at 35 practices) were randomized to receive usual care alone. We found no differences in WOMAC pain scores between the groups at 3 months (adjusted difference -0.58 [95% confidence interval (95% CI) -1.80, 0.63]) or at 12 months (adjusted difference -0.26 [95% CI -1.86, 1.34]). In the subgroup of patients with centralized pain symptoms, we also found no effect of duloxetine compared to usual care alone (adjusted difference -0.32 [95% CI -2.32, 1.67]). We found no effect of duloxetine added to usual care compared to usual care alone in patients with chronic knee or hip OA pain. Another trial including patients with centralized pain symptoms should be conducted to validate our results.
Identifiants
pubmed: 34989159
doi: 10.1002/art.42040
pmc: PMC9313808
doi:
Substances chimiques
Duloxetine Hydrochloride
9044SC542W
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
818-828Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Références
Age Ageing. 2012 Sep;41(5):646-52
pubmed: 22743149
Semin Arthritis Rheum. 2017 Aug;47(1):1-8
pubmed: 28320529
Osteoarthritis Cartilage. 2011 Jun;19(6):647-54
pubmed: 21440077
Osteoarthritis Cartilage. 2019 Nov;27(11):1578-1589
pubmed: 31278997
J Pain Res. 2018 Jul 31;11:1391-1403
pubmed: 30104894
Osteoarthritis Cartilage. 2004 May;12(5):389-99
pubmed: 15094138
Curr Med Res Opin. 2011 Dec;27(12):2361-72
pubmed: 22017192
Cochrane Database Syst Rev. 2014 Sep 17;(9):CD003115
pubmed: 25229835
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Clin J Pain. 2020 May;36(5):336-343
pubmed: 31977373
Arthritis Care Res (Hoboken). 2016 Sep;68(9):1224-31
pubmed: 26713415
Rheumatology (Oxford). 2018 May 1;57(suppl_4):iv43-iv50
pubmed: 29267879
Cochrane Database Syst Rev. 2019 Feb 25;2:CD013273
pubmed: 30801133
BMC Musculoskelet Disord. 2018 May 14;19(1):146
pubmed: 29759063
Disabil Rehabil. 2018 Nov;40(23):2836-2845
pubmed: 28768437
Arthritis Rheumatol. 2020 Feb;72(2):220-233
pubmed: 31908163
BMJ Open. 2017 Sep 11;7(9):e018661
pubmed: 28893757
Lancet. 2017 Jul 8;390(10090):e21-e33
pubmed: 28699595
Ann Intern Med. 1994 Aug 1;121(3):200-6
pubmed: 8017747
J Rheumatol. 1988 Dec;15(12):1833-40
pubmed: 3068365
Osteoarthritis Cartilage. 2015 Jul;23(7):1043-56
pubmed: 25749012
BMC Fam Pract. 2013 Mar 11;14:33
pubmed: 23497253
J Pain Res. 2018 Apr 18;11:809-821
pubmed: 29713194
Arthritis Care Res (Hoboken). 2015 Apr;67(4):519-28
pubmed: 25155472
Eur Psychiatry. 2014 Aug;29(6):365-70
pubmed: 24630746
Pain Med. 2016 Sep;17(9):1694-703
pubmed: 26893116
Ann Intern Med. 2008 Feb 19;148(4):268-77
pubmed: 18283204
Best Pract Res Clin Rheumatol. 2014 Feb;28(1):5-15
pubmed: 24792942
Semin Arthritis Rheum. 1991 Jun;20(6 Suppl 2):40-7
pubmed: 1866629
Rheumatology (Oxford). 2021 May 14;60(5):2206-2216
pubmed: 33175150
J Eval Clin Pract. 2012 Aug;18(4):878-86
pubmed: 21689213
Pain. 2009 Dec;146(3):253-260
pubmed: 19625125
J Rheumatol. 2011 Aug;38(8):1546-51
pubmed: 21632678
Med Care. 2001 Aug;39(8):889-905
pubmed: 11468507
Pain Pract. 2011 Jan-Feb;11(1):33-41
pubmed: 20602715
Osteoarthritis Cartilage. 2019 Jun;27(6):e5-e6
pubmed: 30898622
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):79-84
pubmed: 28967359
Osteoarthritis Cartilage. 2017 Jun;25(6):832-838
pubmed: 28043937
Osteoarthritis Cartilage. 2012 Aug;20(8):805-8
pubmed: 22503814
BMC Musculoskelet Disord. 2019 Apr 22;20(1):174
pubmed: 31010413
Osteoarthritis Cartilage. 2019 Jun;27(6):855-862
pubmed: 30703543
Osteoarthritis Cartilage. 2013 Sep;21(9):1236-42
pubmed: 23973136
Cochrane Database Syst Rev. 2019 May 27;5:CD005522
pubmed: 31132298
Osteoarthritis Cartilage. 2015 May;23(5):826-38
pubmed: 25952353
Allergy. 2017 Apr;72(4):636-644
pubmed: 27696447
BMJ. 2009 Oct 09;339:b4006
pubmed: 19819928
Ann Rheum Dis. 2014 Jul;73(7):1323-30
pubmed: 24553908